1
|
Luque R, Benavides M, del Barco S, Egaña L, García-Gómez J, Martínez-García M, Pérez-Segura P, Pineda E, Sepúlveda JM, Vieito M. SEOM clinical guideline for management of adult medulloblastoma (2020). Clin Transl Oncol 2021; 23:940-947. [PMID: 33792841 PMCID: PMC8057961 DOI: 10.1007/s12094-021-02581-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/02/2021] [Indexed: 11/25/2022]
Abstract
Recent advances in molecular profiling, have reclassified medulloblastoma, an undifferentiated tumor of the posterior fossa, in at least four diseases, each one with differences in prognosis, epidemiology and sensibility to different treatments. The recommended management of a lesion with radiological characteristics suggestive of MB includes maximum safe resection followed by a post-surgical MR < 48 h, LCR cytology and MR of the neuroaxis. Prognostic factors, such as presence of a residual tumor volume > 1.5 cm2, presence of micro- or macroscopic dissemination, and age > 3 years as well as pathological (presence of anaplastic or large cell features) and molecular findings (group, 4, 3 or p53 SHH mutated subgroup) determine the risk of relapse and should guide adjuvant management. Although there is evidence that both high-risk patients and to a lesser degree, standard-risk patients benefit from adjuvant craneoespinal radiation followed by consolidation chemotherapy, tolerability is a concern in adult patients, leading invariably to dose reductions. Treatment after relapse is to be considered palliative and inclusion on clinical trials, focusing on the molecular alterations that define each subgroup, should be encouraged. Selected patients can benefit from surgical rescue or targeted radiation or high-dose chemotherapy followed by autologous self-transplant. Even in patients that are cured by chemorradiation presence of significant sequelae is common and patients must undergo lifelong follow-up.
Collapse
Affiliation(s)
- R. Luque
- Department of Medical Oncology, Hospital Universitario Virgen de Las Nieves, Granada, Spain
| | - M. Benavides
- Department of Medical Oncology, Hospital Regional Universitario Carlos Haya, Malaga, Spain
| | - S. del Barco
- Department of Medical Oncology, Hospital Universitari Dr. Josep Trueta. ICO Girona, Girona, Spain
| | - L. Egaña
- Department of Medical Oncology, Hospital Donostia-Donostia Ospitalea, San Sebastián, Spain
| | - J. García-Gómez
- Department of Medical Oncology, Complexo Hospitalario de Ourense (CHUO), Orense, Spain
| | - M. Martínez-García
- Department of Medical Oncology, Hospital del Mar - Parc de Salut Mar, Barcelona, Spain
| | - P. Pérez-Segura
- Department of Medical Oncology, Hospital Universitario Clínico San Carlos, Madrid, Spain
| | - E. Pineda
- Department of Medical Oncology, Hospital Clinic I Provincial de Barcelona, Barcelona, Spain
| | - J. M. Sepúlveda
- Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - M. Vieito
- Department of Medical Oncology, Hospital Universitario Vall D’Hebron, Barcelona, Spain
| |
Collapse
|
2
|
Fuentes Antras J, Viñuela M, Guevara-Hoyer K, de la Fuente E, Manzano A, Marquina Ospina G, PAZ M, Ocaña A, Fernández-Arquero M, Sánchez-Ramón S, Pérez-Segura P. 1767P Hypercoagulable state, CD4+ T-lymphocytopenia, dysregulated cytotoxicity and monocyte upregulation in COVID-19 positive cancer patients presenting with severe pneumonia. Ann Oncol 2020. [PMCID: PMC7506314 DOI: 10.1016/j.annonc.2020.08.1831] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/30/2022] Open
|
3
|
Muñoz-Langa J, Jimenez-Fonseca P, Carmona-Bayonas A, de Castro EM, Pérez-Segura P, Cánovas MS, Gomez D, Moran LO, de Tejada MBG, Seguí E, López GB, Adrián SG, Campos MC, Olmos VP, Portero BO, Moyano MS, Crespo JAS, Sánchez LT, Rebollo MA, Rivas PO, Altozano JP, Lescure ÁR, Muñoz-Martín A. Rationale, design and methodology of TESEO study: a registry of thrombosis and neoplasia of SEOM (Spanish Society of Medical Oncology). Clin Transl Oncol 2020; 23:799-811. [PMID: 32789772 DOI: 10.1007/s12094-020-02472-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2020] [Accepted: 08/03/2020] [Indexed: 11/26/2022]
Abstract
BACKGROUND AND RATIONALE Thromboembolic complications are a serious, preventable and common event in cancer patients that contributes to increasing morbidity and mortality. Despite increasing knowledge on cancer-associated thrombosis (CAT), there are still several aspects of diagnosis, clinical management, treatment and prognosis with uncertainties that are under-represented in randomized clinical trials. For this reason, the Spanish Society of Medical Oncology (SEOM) launched in June 2018 a registry of CAT. METHODS/DESIGN TESEO is an ongoing prospective, non-interventional, multicentric study in consecutive cancer patients with newly diagnosed of thromboembolic event (TEE). Eligibility criteria include being > 18 years with a histologically confirmed diagnosis of cancer and a symptomatic or incidental TEE confirmed with an imaging technique in the previous month or any time after the cancer diagnosis and signing of informed consent. The study consists of two types of integrated but independent prospective registries. Regular CAT sub-registry includes information on patient's cancer´s characteristics, anticoagulant treatment provided and outcome data. Special CAT sub-registry includes variables related to special situations of CAT that comprise patients with severe kidney failure, thrombocytopenia, high risk of bleeding related to the cancer or with coexistence of bleeding and patients who receive new treatments such a targeted therapy, antiangiogenics agents and immunotherapy. The registry considers the status of the cancer and the time to assess how the prognosis is changed based on when the thrombus occurs. Some outcomes such as rethrombosis, major bleeding, tumor progression and survival will be valued in various time intervals including 1, 3, 6 and 12 months after the even in the first year; and then every 6 months until the patient's death. RESULTS After 18 months and with 35 centers and researchers, the registry has 1128 patients. CONCLUSION TESEO registry will provide clinical real-world evidence for prevention, treatment and complications of CAT in different scenarios that are under-represented in randomized clinical trials.
Collapse
Affiliation(s)
- J Muñoz-Langa
- Medical Oncology Department, Hospital Clínico Universitario de Valencia, Avinguda Blasco Ibáñez nº 17, Valencia, 46010, Spain.
| | - P Jimenez-Fonseca
- Medical Oncology Department, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain
| | - A Carmona-Bayonas
- Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, University of Murcia, IMIB, Murcia, Spain
| | - E M de Castro
- Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
| | - P Pérez-Segura
- Medical Oncology Department, Hospital Universitario Clínico San Carlos, Madrid, Spain
| | - M S Cánovas
- Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, University of Murcia, IMIB, Murcia, Spain
| | - D Gomez
- Medical Oncology Department, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain
| | - L O Moran
- Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain
| | - M B G de Tejada
- Medical Oncology Department, Hospital Universitario Val d´Hebron, Barcelona, Spain
| | - E Seguí
- Medical Oncology Department, Hospital Universitario Santa Creu i Sant Pau, Barcelona, Spain
| | - G B López
- Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Tenerife, Spain
| | - S G Adrián
- Medical Oncology Department, Hospital Universitario de Móstoles, Madrid, Spain
| | - M C Campos
- Medical Oncology Department, Hospital Universitario Lucus Augusti, Lugo, Spain
| | - V P Olmos
- Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain
| | - B O Portero
- Medical Oncology Department, Hospital Universitario Infanta Leonor, Madrid, Spain
| | - M S Moyano
- Medical Oncology Department, Hospital Universitario de Jerez de la Frontera, Cádiz, Spain
| | - J A S Crespo
- Medical Oncology Department, Hospital Virgen de la Luz, Cuenca, Spain
| | - L T Sánchez
- Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain
| | - M A Rebollo
- Medical Oncology Department, Institut Català D'Oncologia (ICO), L'Hospitalet, Barcelona, Spain
| | - P O Rivas
- Medical Oncology Department, Hospital Central de la Defensa Gomez Ulla, Madrid, Spain
| | - J P Altozano
- Medical Oncology Department, Hospital Virgen de los Lirios, Alcoy, Alicante, Spain
| | - Á R Lescure
- Medical Oncology Department, Hospital General Universitario de Elche, Elche, Spain
| | - A Muñoz-Martín
- Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain
| |
Collapse
|
4
|
García-Alfonso P, García-Carbonero R, García-Foncillas J, Pérez-Segura P, Salazar R, Vera R, Ramón Y Cajal S, Hernández-Losa J, Landolfi S, Musulén E, Cuatrecasas M, Navarro S. Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clin Transl Oncol 2020; 22:1976-1991. [PMID: 32418154 PMCID: PMC7505870 DOI: 10.1007/s12094-020-02357-z] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2019] [Accepted: 04/28/2020] [Indexed: 12/16/2022]
Abstract
In this update of the consensus of the Spanish Society of Medical Oncology (Sociedad Española de Oncología Médica—SEOM) and the Spanish Society of Pathology (Sociedad Española de Anatomía Patológica—SEAP), advances in the analysis of biomarkers in advanced colorectal cancer (CRC) as well as susceptibility markers of hereditary CRC and molecular biomarkers of localized CRC are reviewed. Recently published information on the essential determination of KRAS, NRAS and BRAF mutations and the convenience of determining the amplification of human epidermal growth factor receptor 2 (HER2), the expression of proteins in the DNA repair pathway and the study of NTRK fusions are also evaluated. From the pathological point of view, the importance of analysing the tumour budding and poorly differentiated clusters, and its prognostic value in CRC is reviewed, as well as the impact of molecular lymph node analysis on lymph node staging in CRC. The incorporation of pan-genomic technologies, such as next-generation sequencing (NGS) and liquid biopsy in the clinical management of patients with CRC is also outlined. All these aspects are developed in this guide, which, like the previous one, will remain open to any necessary revision in the future.
Collapse
Affiliation(s)
- P García-Alfonso
- Departament of Medical Oncology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
| | - R García-Carbonero
- Departament of Medical Oncology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), UCM, CNIO, CIBERONC, Madrid, Spain
| | - J García-Foncillas
- Departament of Medical Oncology, Hospital Universitario Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain
| | - P Pérez-Segura
- Departament of Medical Oncology, Hospital Clínico Universitario San Carlos, CIBERONC, Madrid, Spain
| | - R Salazar
- Departament of Medical Oncology, ICO L'Hospitalet, Oncobell Program (IDIBELL), CIBERONC, Hospitalet de Llobregat, Spain
| | - R Vera
- Departament of Medical Oncology, Complejo Hospitalario de Navarra; Navarrabiomed, IDISNA, Pamplona, Spain
| | - S Ramón Y Cajal
- Department of Pathology, Hospital Universitario Vall D'Hebron, CIBERONC, Barcelona, Spain
| | - J Hernández-Losa
- Department of Pathology, Hospital Universitario Vall D'Hebron, CIBERONC, Barcelona, Spain
| | - S Landolfi
- Department of Pathology, Hospital Universitario Vall D'Hebron, CIBERONC, Barcelona, Spain
| | - E Musulén
- Department of Pathology, Hospital Universitari General de Catalunya, Grupo Quirónsalud, Sant Cugat del Vallès, Spain.,Cancer Epigenetics Group, Institut de Recerca Contra La Leucèmia Josep Carreras, Badalona, Spain
| | - M Cuatrecasas
- Department of Pathology, Hospital Clinic, CIBERehd, Barcelona, Spain
| | - S Navarro
- Department of Pathology, University of Valencia, Hospital Clínico Universitario de Valencia, CIBERONC, Valencia, Spain
| |
Collapse
|
5
|
Cabezas-Camarero S, Pérez-Alfayate R, Puebla F, Cabrera-Martín MN, Pérez-Segura P. Increased clinical and plasma EBV DNA responses to platinum-gemcitabine after nivolumab in patients with heavily platinum-pretreated nasopharyngeal cancer. Oral Oncol 2019; 103:104527. [PMID: 31866218 DOI: 10.1016/j.oraloncology.2019.104527] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2019] [Accepted: 12/14/2019] [Indexed: 02/05/2023]
Affiliation(s)
- S Cabezas-Camarero
- Medical Oncology Department, Hospital Clínico Universitario San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain; Center Affiliate to CIBERONC, Instituto Carlos III, Madrid, Spain.
| | - R Pérez-Alfayate
- Neurosurgery Department, Hospital Clínico Universitario San Carlos, Madrid, Spain
| | - F Puebla
- Radiation Oncology Department, Hospital Clínico Universitario San Carlos, Madrid, Spain
| | - M N Cabrera-Martín
- Nuclear Medicine Department, Hospital Clínico Universitario San Carlos, Madrid, Spain
| | - P Pérez-Segura
- Medical Oncology Department, Hospital Clínico Universitario San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain; Center Affiliate to CIBERONC, Instituto Carlos III, Madrid, Spain
| |
Collapse
|
6
|
Cabezas-Camarero S, Abad DG, de la Varga LU, Jaime JC, Pérez-Segura P. Dynamic changes in neutrophil-to-lymphocyte ratio of head and neck cancer patients receiving nivolumab in a real-world setting. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz449.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
7
|
Salgado M, Sepulveda Sanchez J, del barco S, Pineda E, Fuster J, Navarro Martin M, Herrero Ibañez A, Alonso M, Perez J, Mesia C, Munoz-Langa J, de las Penas Bataller R, Peralta S, Olier C, Pérez-Segura P, Estival A, Carrato C, Saez C, Gil M, Balana C. Extending temozolomide longer than six cycles in glioblastoma: Results of the randomized GEINO-014 trial. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz243.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
8
|
Pérez-Peña J, Fekete J, Páez R, García-Sáenz J, García-Barberán V, Pérez-Segura P, Pandiella A, Gyorffy B, Ocaña A, Manzano A. A transcriptomic immunologic signature predicts favorable outcome in neoadjuvant chemotherapy treated triple negative breast tumours. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz253.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
9
|
Balana C, Sepulveda J, Pineda E, Vaz M, Mesia C, Fuster J, Girones R, Muñoz-Langa J, Navarro M, Alonso M, Gil Gil M, Herrero A, Estival A, Gallego O, Peralta S, Olier C, Pérez-Segura P, Covela M, Martinez García M, Domenech M, Carrato C, Sanz C, Velarde J, Berrocal A, Luque R, De las Peñas R, Del Barco S. P14.58 Extending adjuvant temozolomide longer than six cycles doesn’t add any benefit to glioblastoma patients according to the randomized GEINO-014 TRIAL. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz126.293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
BACKGROUND
Standard treatment of glioblastoma (GBM) is focal radiation with concomitant and adjuvant temozolomide (TMZ) for 6 cycles. The GEINO-14-01 trial (NCT02209948) investigated the role of extending adjuvant TMZ to 12 cycles in a randomized multicenter study.
MATERIAL AND METHODS
Between Aug/2014 and Nov/2018, 166 patients (p) were screened and 159 randomized to extend (80p) or not (79p) TMZ treatment to 12 cycles after proving stable disease in the MRI performed before inclusion. The trial was stratified by MGMT status and presence or absence of residual disease (defined as a residual enhancement larger than 1cm on the MRI). The primary endpoint was differences in 6monthsPFS, secondary endpoints were differences in PFS, OS, toxicity, between arms and per stratification factors.
RESULTS
Median age was 60.4 (range 29–83), 97p (61%) were methylated and 83 p (52.2%) were reported with residual disease. Median (m) PFS was 7.9 months (95%CI: 6.1–9.8) and mOS: 20.9 (95%CI: 17.6–24.1). A methylated status was a factor of better PFS (HR=0.29, 95% CI 0.46–0.95; p=0.029) and better OS (HR= 0.43: 95% CI 0.28–0.66; p=0.000) as well as the absence of residual disease (PFS: HR = 0.84: 95% CI =0.71–1.01; p=0.068; OS: HR=0.77, 95%CI 0.63–0.96; p=0.019). We didn’t find any difference in PFS (HR=1.02, 95%CI 0.85–1.21; p=0.82), or OS (HR=0.90; 0.73–1.11; p=0.34) on extending treatment with temozolomide longer than 6 cycles.
CONCLUSION
There is no benefit of continuing TMZ treatment for more than 6 cycles in the adjuvant treatment of glioblastoma. Final data will be presented at the congress. Supported by a Grant of the ISCIII: PI13/01751
Collapse
Affiliation(s)
- C Balana
- Institut Catala Oncologia Badalona, Badalona, Spain
| | - J Sepulveda
- Hospital Universitario 12 de Octubre, Madrid, Spain
| | - E Pineda
- Hospital Clinic de Barcelona, Barcelona, Spain
| | - M Vaz
- Hospital Ramon y Cajal, Madrid, Spain
| | - C Mesia
- Institut Catala Oncologia Hospital Duran y Reynalds, Hospitalet de Llobregat, Spain
| | - J Fuster
- Hospital Universitari Son Espases, Palma de Mallorca, Spain
| | - R Girones
- Hospital Universitari i Politècnic la Fe, Valencia, Spain
| | - J Muñoz-Langa
- Hospital Universitari i Politècnic la Fe, Valencia, Spain
| | - M Navarro
- Hospital Universitario de Salamanca, Salamanca, Spain
| | - M Alonso
- Hospital Universitario la Virgen del Rocio, Sevilla, Spain
| | - M Gil Gil
- Institut Catala Oncologia Hospital Duran y Reynalds, Hospitalet de Llobregat, Spain
| | - A Herrero
- Hospital Universitario Miguel Servet, Zaragoza, Spain
| | - A Estival
- Institut Catala Oncologia Badalona, Badalona, Spain
| | - O Gallego
- Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - S Peralta
- Hospital Universitari Sant Joan de Reus, Reus, Spain
| | - C Olier
- Hospital Universitario Fundacion Alcorcon, Alcorcon, Spain
| | | | - M Covela
- Hospital Universitario Lucus Augusti, Lugo, Spain
| | | | - M Domenech
- Institut Catala Oncologia Badalona, Badalona, Spain
| | - C Carrato
- Hospital Universitari Germans Trias i Pujol, Badalona, Spain
| | - C Sanz
- Hospital Universitari Germans Trias i Pujol, Badalona, Spain
| | - J Velarde
- Institut Catala Oncologia Badalona, Badalona, Spain
| | - A Berrocal
- Hospital General Universitari de Valencia, Valencia, Spain
| | - R Luque
- HospitalUniversitario Virgen de las Nieves, Granada, Spain
| | | | - S Del Barco
- Institut Catala Oncologia Hospital Universitari Josep Trueta, Girona, Spain
| |
Collapse
|
10
|
Cabezas-Camarero S, Pérez-Alfayate R, Casado Fariñas I, Sáiz-Pardo Sanz M, Subhi-Issa I, Pérez-Segura P, García-Barberán V. Relation between IDH1 status, histologic grade, immune-cell infiltration and expression of immune-related genes in patients with gliomas. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy493.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
11
|
Pérez-Segura P, Palacio JE, Vázquez L, Monereo S, de Las Peñas R, de Icaya PM, Grávalos C, Lecube A, Blasco A, García-Almeida JM, Barneto I, Goday A. Peculiarities of the obese patient with cancer: a national consensus statement by the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology. Clin Transl Oncol 2017; 19:682-694. [PMID: 28074400 DOI: 10.1007/s12094-016-1601-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2016] [Accepted: 12/16/2016] [Indexed: 12/14/2022]
Abstract
The relationship between obesity and cancer is clear and is present at all times during course of the disease. The importance of obesity in increasing the risk of developing cancer is well known, and some of the most prevalent tumours (breast, colorectal, and prostate) are directly related to this risk increase. However, there is less information available on the role that obesity plays when the patient has already been diagnosed with cancer. Certain data demonstrate that in some types of cancer, obese patients tolerate the treatments more poorly. Obesity is also known to have an impact on the prognosis, favouring lower survival rates or the appearance of secondary tumours. In this consensus statement, we will analyse the scientific evidence on the role that obesity plays in patients already diagnosed with cancer, and the available data on how obesity control can improve the quality of daily life for the cancer patient.
Collapse
Affiliation(s)
- P Pérez-Segura
- Servicio de Oncología Médica, Hospital Clínico Universitario San Carlos, Calle Profesor Martín Lagos, s/n, 28040, Madrid, Spain.
| | - J E Palacio
- Servicio de Endocrinología, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Tenerife, Spain
| | - L Vázquez
- Servicio de Oncología Médica, Complejo Hospitalario de Pontevedra, Pontevedra, Spain
| | - S Monereo
- Servicio de Endocrinología, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - R de Las Peñas
- Servicio de Oncología Médica, Consorcio Hospitalario Provincial de Castellón, Castellón de la Plana, Castellón, Spain
| | - P Martínez de Icaya
- Servicio de Endocrinología, Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain
| | - C Grávalos
- Servicio de Oncología Médica, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - A Lecube
- Servicio de Endocrinología, Hospital Arnau de Vilanova, Lleida, Spain
| | - A Blasco
- Servicio de Oncología Médica, Consorcio Hospital General Universitario de Valencia, Valencia, Spain
| | - J M García-Almeida
- Servicio de Endocrinología, Hospital Universitario Virgen de la Victoria, Málaga, Spain
| | - I Barneto
- Servicio de Oncología Médica, Hospital Universitario Reina Sofía, Córdoba, Spain
| | - A Goday
- Servicio de Endocrinología, Hospital del Mar, Barcelona, Spain.,Departament de Medicina, IMIM Institut Mar de Investigacions Mediques, CiberOBN, Universitat Autònoma de Barcelona, Barcelona, Spain
| |
Collapse
|
12
|
Pérez-Segura P, Manneh R, Ceballos I, García A, Benavides M, Fuster J, Vaz MA, Cano JM, Berros JP, Covela M, Moreno V, Quintanar T, García Bueno JM, Fernández I, Sepúlveda J. GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status. Clin Transl Oncol 2015; 18:805-12. [DOI: 10.1007/s12094-015-1444-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2015] [Accepted: 10/26/2015] [Indexed: 11/30/2022]
|
13
|
Pollan M, Ramon y Cajal T, Chirivella I, Miranda J, Teule A, Brunet J, Sanchez-Heras AB, Llort G, Balmañà J, Carvajal V, Hernandez-Agudo E, Juan-Fita MJ, Tena-García I, Robles L, Guillén C, Pérez-Segura P, Luque-Molina MS, Hernando S. Mammographic Density and Breast Cancer in BRCA1/BRCA2 Carriers. Int J Epidemiol 2015. [DOI: 10.1093/ije/dyv096.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Goday A, Barneto I, García-Almeida JM, Blasco A, Lecube A, Grávalos C, Martínez de Icaya P, de las Peñas R, Monereo S, Vázquez L, Palacio JE, Pérez-Segura P. Obesity as a risk factor in cancer: A national consensus of the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology. Clin Transl Oncol 2015; 17:763-71. [PMID: 26036853 DOI: 10.1007/s12094-015-1306-y] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2015] [Accepted: 05/18/2015] [Indexed: 01/16/2023]
Abstract
In the last few years, many prospective studies have demonstrated a clear association between obesity and cancers of the colon and rectum, breast in post-menopausal women, endometrium, kidney, oesophagus and pancreas. Obesity is also associated with a high risk of recurrence and cancer-related death. The pathophysiology of obesity involves various changes that may be implicated in the relationship between obesity and cancer, such as excess inflammatory cytokines and chronic inflammation, hyperinsulinaemia, insulin resistance, and raised leptin and oestrogens. The Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology have signed a cooperation agreement to work together towards reducing the impact of obesity in cancer. Preventing obesity prevents cancer.
Collapse
Affiliation(s)
- A Goday
- Servicio de Endocrinología, Hospital del Mar, Passeig Marítim de la Barceloneta 25-29, 08003, Barcelona, Spain. .,IMIM Institut Mar de Investigacions Mediques, CiberOBN, Passeig Marítim de la Barceloneta 25-29, 08003, Barcelona, Spain.
| | - I Barneto
- Servicio de Oncología Médica, Hospital Universitario Reina Sofía, Córdoba, Spain
| | - J M García-Almeida
- Servicio de Endocrinología, Hospital Universitario Virgen de la Victoria, Málaga, Spain
| | - A Blasco
- Servicio de Oncología Médica, Consorcio Hospital General Universitario de Valencia, Valencia, Spain
| | - A Lecube
- Servicio de Endocrinología, Hospital Arnau de Vilanova, Lleida, Spain
| | - C Grávalos
- Servicio de Oncología Médica, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - P Martínez de Icaya
- Servicio de Endocrinología, Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain
| | - R de las Peñas
- Servicio de Oncología Médica, Consorcio Hospitalario Provincial de Castellón, Castelló de la Plana, Castellón, Spain
| | - S Monereo
- Servicio de Endocrinología, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - L Vázquez
- Servicio de Oncología Médica, Complejo Hospitalario de Pontevedra, Pontevedra, Spain
| | - J E Palacio
- Servicio de Endocrinología, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Tenerife, Spain
| | - P Pérez-Segura
- Servicio de Oncología Médica, Hospital Clínico Universitario San Carlos, Madrid, Spain
| |
Collapse
|
15
|
Andrés R, Pajares I, Balmaña J, Llort G, Ramón y Cajal T, Chirivella I, Aguirre E, Robles L, Lastra E, Pérez-Segura P, Bosch N, Yagüe C, Lerma E, Godino J, Miramar MD, Moros M, Astier P, Saez B, Vidal MJ, Arcusa A, Ramón y Cajal S, Calvo MT, Tres A. Association of BRCA1 germline mutations in young onset triple-negative breast cancer (TNBC). Clin Transl Oncol 2013; 16:280-4. [DOI: 10.1007/s12094-013-1070-9] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2013] [Accepted: 06/16/2013] [Indexed: 11/24/2022]
|
16
|
Manzano A, Pérez-Segura P. Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention? ScientificWorldJournal 2012; 2012:327341. [PMID: 22649288 PMCID: PMC3353298 DOI: 10.1100/2012/327341] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2011] [Accepted: 11/17/2011] [Indexed: 12/21/2022] Open
Abstract
Colorectal cancer (CRC) is presently one of the most common causes of cancer-related death in our setting and affects a great number of people each year. Screening strategies are commonly used but they do not seem enough to avoid CRC development or prevent completely its mortality. Because of this fact other prevention strategies have gained interest in recent years. Chemoprevention seems to be an attractive option in this setting and several drugs have been studied in this field. This review is focused on salicylates, nonsteroidal anti-inflammatory drugs (NSAIDs) and cycloxygenase-2 inhibitors (COXIBs), whose mechanism of action could be directly related to colon cancer chemoprevention.
Collapse
Affiliation(s)
- A Manzano
- Oncology Department, Hospital Clínico San Carlos, 28040 Madrid, Spain
| | | |
Collapse
|
17
|
Custodio A, Pérez-Segura P, Zamorano J, López-Farrã A, Olivera E, Puente J, Diaz-Rubio E. Analysis of plasma proteome from BRCA1/BRCA2 mutation carriers as modifier risk factor of breast cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.1549] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
18
|
Custodio A, Pérez-Segura P, Zamorano J, López-Farré A, Olivera E, Puente J, Díaz-Rubio E. PP38 Proteomic analysis of plasma from BRCA1/BRCA2 mutation carriers as modifier risk factor of breast cancer. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)72153-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
19
|
Bodas A, Pérez-Segura P, Maluenda C, Caldés T, Olivera E, Díaz-Rubio E. Lynch syndrome in a 15-year-old boy. Eur J Pediatr 2008; 167:1213-5. [PMID: 18183421 DOI: 10.1007/s00431-007-0650-5] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/20/2007] [Accepted: 12/04/2007] [Indexed: 11/30/2022]
Abstract
Hereditary nonpolyposis colorectal cancer (HNPCC), or Lynch syndrome, dominantly inherited, is characterized by the development of a variety of cancers due to germline mutations in DNA mismatch repair genes (MMR). This syndrome was diagnosed in a 15-year-old boy because his father and grandmother were also found to have the same kind of cancer. Microsatellite instability prompted a search for germline mutations in the MLH1, MSH2, MSH6, and PMS2 genes. Use of immunohistochemical staining for MMR proteins, genomic sequencing, and deletion studies, evidenced MSH2 axonal deletion. Neoplastic lesions of colon are most often encountered in the adult population but can, on rare occasions, be found in younger patients. We would like to emphasize the importance of suspecting Lynch syndrome and performing genetic studies, even in young patients, when there is a family history of colorectal cancer.
Collapse
Affiliation(s)
- A Bodas
- Department of Pediatrics, Hospital Clínico San Carlos, Madrid, Spain.
| | | | | | | | | | | |
Collapse
|
20
|
Pérez-Segura P, Siso I, Luque R, Olivera H, Díaz S, Mayol J, Bueno C, Puente J, Díaz-Rubio E. Iatrogenic intestinal obstruction: a rare complication of capsule endoscopy in a patient with familial adenomatous polyposis. Endoscopy 2007; 39 Suppl 1:E298-9. [PMID: 17957618 DOI: 10.1055/s-2007-966595] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- P Pérez-Segura
- Medical Oncology Department (Genetic Counselling Unit), Hospital Clínico San Carlos, Madrid, Spain.
| | | | | | | | | | | | | | | | | |
Collapse
|
21
|
de la Hoya M, Díez O, Pérez-Segura P, Godino J, Fernández JM, Sanz J, Alonso C, Baiget M, Díaz-Rubio E, Caldés T. Pre-test prediction models of BRCA1 or BRCA2 mutation in breast/ovarian families attending familial cancer clinics. J Med Genet 2003; 40:503-10. [PMID: 12843322 PMCID: PMC1735524 DOI: 10.1136/jmg.40.7.503] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
OBJECTIVE To test whether statistical models developed to calculate pre-test probability of being a BRCA1/2 carrier can differentiate better between the breast/ovarian families to be referred to the DNA test laboratory. STUDY DESIGN A retrospective analysis was performed in 109 Spanish breast/ovarian families previously screened for germline mutations in both the BRCA1 and BRCA2 genes. Four easy to use logistic regression models originally developed in Spanish (HCSC model), Dutch (LUMC model), Finnish (HUCH model), and North American (U Penn model) families and one model based on empirical data of Frank 2002 were tested. A risk counsellor was asked to assign a subjective pre-test probability for each family. Sensitivity, specificity, negative and positive predictive values, and areas under receiver operator characteristics (ROC) curves were calculated in each case. Correlation between predicted probability and mutation prevalence was tested. All statistical tests were two sided. RESULTS Overall, the models performed well, improving the performances of a genetic counsellor. The median ROC curve area was 0.80 (range 0.77-0.82). At 100% sensitivity, the median specificity was 30% (range 25-33%). At 92% sensitivity, the median specificity was 42% (range 33.3-54.2%) and the median negative predictive value was 93% (range 89.7-98%). BRCA1 families tended to score higher risk than BRCA2 families in all models tested. CONCLUSIONS All models increased the discrimination power of an experienced risk counsellor, suggesting that their use is valuable in the context of clinical counselling and genetic testing to optimise selection of patients for screening and allowing for more focused management. Models developed in different ethnic populations performed similarly well in a Spanish series of families, suggesting that models targeted to specific populations may not be necessary in all cases. Carrier probability as predicted by the models is consistent with actual prevalence, although in general models tend to underestimate it. Our study suggests that these models may perform differently in populations with a high prevalence of BRCA2 mutations.
Collapse
Affiliation(s)
- M de la Hoya
- Laboratory of Molecular Oncology, Hospital Clínico San Carlos, Madrid, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
García-Sáenz JA, Martín M, Casado A, Pérez-Segura P, Manrique I, Flores L, Macias JA, Cámara JC, Perezagua C, Díaz-Rubio E. Immediate vs. delayed imipenem treatment in cancer patients with profound neutropenia induced by high-dose chemotherapy: results of a randomized study. Rev Esp Quimioter 2002; 15:257-63. [PMID: 12582429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/28/2023]
Abstract
A study was carried out to compare the use of prophylactic imipenem administered at the onset of profound neutropenia (immediate) with therapeutic imipenem administered at the onset of neutropenic fever (delayed) in cancer patients treated with high-dose chemotherapy. A total of 65 patients who were scheduled to receive two cycles of high-dose cyclophosphamide, etoposide, cisplatin (CEP) chemotherapy were randomized to receive imipenem either at presentation of neutropenia (immediate imipenem arm, prophylactic arm) or at commencement of neutropenic fever (delayed imipenem arm, therapeutic arm). Treatment was crossed over when the second CEP chemotherapy cycle was received. Of the 65 patients, 41 received the two planned cycles and 24 received only the first. Compared with the delayed imipenem arm, the immediate imipenem arm was associated with lower fever incidence (86.3% vs. 100%, p=0.0142) and Gram-negative bacteria infection [4/51 (7.8%) vs. 14/55 (25.5%), OR=0.24, p =0.031]. There were fewer episodes of pneumonia (2% vs. 12.7%), septic shock (0% vs. 3.6%) and deaths from infection (0% vs. 3.6%), but these differences did not reach statistical significance. With regard to delayed imipenem, for every seven patients with immediate imipenem, one episode of febrile neutropenia was avoided; for every six patients administered immediate imipenem, one case of Gram-negative infection was avoided; and for every nine patients administered immediate imipenem, one episode of pneumonia was avoided. There were no differences in the incidence of Gram-positive infections nor in the length of hospitalization between the two treatment arms. In conclusion, compared to its conventional delayed use, immediate imipenem significantly reduces the frequency of febrile neutropenia and Gram-negative infections in patients with high-dose chemotherapy.
Collapse
Affiliation(s)
- J A García-Sáenz
- Department of Medical Oncology, Hospital Universitario San Carlos, Madrid, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
|
24
|
Pérez-Segura P, Colmenarejo Rubio A. [Syndrome of the superior vena cava. (Compilation of the cases of the San Carlos University Clinical Hospital in Madrid in the last 5 years and review of the literature)]. An Med Interna 1995; 12:560-4. [PMID: 8804174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
We show in this work the experience of "San Carlos" University Hospital, Madrid, about superior vena cava syndrome in the last 5 years, and we make an intensive review of literature. We have documented 14 cases of superior vena cava syndrome in our Hospital, in patients between 20 and 90 years of age (x: 61 years) and sex distribution of males (42.8%) and females (57.2%).
Collapse
|